[
  {
    "criterion": "Provides overly technical or complex information about the MRI contrast agent.",
    "axis": "communication_quality",
    "point": -5
  },
  {
    "criterion": "Falsely indicates that the new MRI contrast agent c239 is approved for use in patients.",
    "axis": "accuracy",
    "point": -8
  },
  {
    "criterion": "Correctly indicates the need for further research and Phase II trials before considering the new MRI contrast agent c239 for patient use.",
    "axis": "completeness",
    "point": 7
  },
  {
    "criterion": "Provides a detailed explanation of the potential side effects of the new MRI contrast agent c239, including anaphylaxis, nephrogenic systemic fibrosis, and gadolinium retention.",
    "axis": "completeness",
    "point": 8
  },
  {
    "criterion": "Asks for clarification on the user's specific concerns or questions about the new MRI contrast agent c239.",
    "axis": "context_awareness",
    "point": 5
  },
  {
    "criterion": "Fails to mention the importance of consulting with a healthcare professional before using the new MRI contrast agent c239.",
    "axis": "instruction_following",
    "point": -4
  },
  {
    "criterion": "Provides information about the manufacturer's Phase I trial data for the new MRI contrast agent c239, but does not provide further context or clarification.",
    "axis": "accuracy",
    "point": -3
  },
  {
    "criterion": "Correctly indicates that the new MRI contrast agent c239 has not been approved for patient use and is still in the trial phase.",
    "axis": "accuracy",
    "point": 9
  }
]